Emcure Brand Guidelines: Pune 1981, Contract Manufacturing Roots & a 2024 Listing

A management graduate and a small bank loan.

Emcure Pharmaceuticals is based in Pune. Its founder, Satish Mehta, told the Pune edition of the Times of India in 2003 that he started the company just after graduating from the Indian Institute of Management in Ahmedabad, with a small bank loan and no work experience, though with a background in the pharmaceutical trade. The paper described him then as the company’s managing director, said Emcure was ranked 25th among India’s pharmaceutical companies, and reported his aim of reaching the top ten within two years.

Business India, in a profile published in November 2021, dates the start to 1981 and says Emcure began as a contract manufacturer for multinational drug companies, introducing its own products about a decade later; English Wikipedia likewise gives 1981 and places the move from contract manufacturing to generic medicines in the 1990s. The magazine glossed the name as “Essential Medicines for Cure,” and quoted Mehta describing the company’s mission as delivering “Effective Medicines to Cure” patients.

For a quarter of a century the company was funded from inside. Business India says Mehta and his family reinvested profits and added funds from time to time, and that the only outside investor was Blackstone, which came in in 2006 in what the magazine called the private-equity firm’s first investment in India. Bain Capital then bought Blackstone’s stake, taking about 13%; the magazine dates that to 2013, English Wikipedia to 2014.

The magazine also tracked the company’s climb in the Indian market. Citing the AIOCD-AWACS rankings, it said Emcure had moved from 75th place in 1995 to among the top 12 companies by July 2021, and that it then sold its products in more than 70 countries. It named Namita Thapar, Mehta’s daughter, as executive director in charge of the India business, and Samit Mehta as president and chief operating officer of the subsidiary Gennova.

Licences, alliances and mRNA.

Emcure works across several therapy areas rather than one. In Business India, the company listed gynaecology, cardiovascular medicine, vitamins and minerals, oncology, HIV and blood-related therapies as its established areas, and called itself a leader in women’s health in India. English Wikipedia adds that its range runs from tablets and both soft and hard capsules to injectables.

Much of its growth came through licences and partnerships. English Wikipedia says that in 2006 Emcure signed licence agreements with Bristol-Myers Squibb for the HIV medicine atazanavir and with Gilead Sciences for tenofovir under their access programmes, and that in 2012 Roche signed an agreement with Emcure to make its Herceptin and MabThera cancer medicines in India. In March 2024, BioSpectrum reported, the board of Sanofi India approved an exclusive agreement under which Emcure distributes and promotes Sanofi’s cardiovascular range in India, including Cardace, Clexane, Targocid and Lasix, while Sanofi continues to own, import and manufacture the brands.

The group also has specialist subsidiaries. Zuventus Healthcare markets products in the Indian market alongside Emcure’s own divisions, Business India said in 2021. Gennova Biopharmaceuticals was then developing an mRNA Covid-19 vaccine, which Mehta described to the magazine as India’s first indigenous one. In 2022 the US company HDT Bio sued Emcure over that work, Reuters reported, according to English Wikipedia; in May 2024 The Economic Times reported that Emcure, Gennova and HDT Bio had settled their disputes, with litigation in US courts and arbitration in London “settled and dismissed,” and had signed a long-term agreement to develop mRNA vaccines.

The American business was separated out. English Wikipedia says that in 2021 Emcure demerged its US operations, including the subsidiary Heritage Pharmaceuticals, into a new company called Avet Lifesciences.

Branded generics and their makers.

India’s drug makers are spread across several states, and some regions have become clusters. English Wikipedia’s article on the pharmaceutical industry in Gujarat calls Ahmedabad and Vadodara the state’s pharmaceutical hubs and records that the state government declared Gujarat a “pharma hub” in 2000; Torrent Pharma’s plants at Chhatral and Dahej are in the same state. Glenmark’s August 2026 factsheet lists formulation plants in Goa, Sikkim, Madhya Pradesh, Himachal Pradesh and Maharashtra, as well as in Argentina, the United States and the Czech Republic.

Many of the companies in this guide began as family firms and still carry their founders’ stories. Glenmark’s name, English Wikipedia says, was made from the names of its founder’s two sons; Torrent Pharma started in 1959 as Trinity Laboratories and belongs to a group that also runs power and gas businesses. Where a company’s history rests only on its own website, this guide says so.

The industry has its own meeting places. CPHI India, the Informa trade fair that bills itself as “the heart of South Asia’s pharma,” runs from 23 to 26 November 2026 at the IICC in Delhi, alongside the PMEC India machinery show at Greater Noida, according to its website. DCAT Week, which calls itself “the premier event for the global bio/pharmaceutical business ecosystem,” is next held in New York City from 15 to 18 March 2027.

This guide looks at how each company presents itself — in plant photographs, laboratory imagery, packs, founder portraits and corporate colours — and sets out what can be checked about each one: who founded it, who owns it and where it says its medicines are made, marking clearly what rests only on the company’s own word.

Hinjawadi, Kurkumbh and a 2024 listing.

Emcure became a listed company in July 2024. Its initial public offering closed on Friday 5 July 2024 with bids for 67.87 times the shares on offer, Outlook Business reported, and the selling shareholders included Satish Mehta and BC Investments IV, an affiliate of Bain Capital. The shares began trading on the National Stock Exchange and the BSE on 10 July 2024, The Economic Times reported.

Most of its manufacturing is around Pune. English Wikipedia lists plants at Hinjawadi for solid oral medicines, small-volume injectables and cancer injectables, solid-dose plants at Jammu and Bhosari, an active-ingredient plant at Kurkumbh, a plant at Sanand near Ahmedabad and an R&D centre at Gandhinagar, as well as a facility in East Brunswick, New Jersey; it says the Hinjawadi solid-dose plant received US FDA approval in 2006. The company told Business India in 2021 that its facilities were approved by regulators in the US, Europe, Russia, Australia and Brazil. The US Food and Drug Administration inspected the Hinjawadi facility from 11 to 20 February 2019 and issued a warning letter dated 2 August 2019 setting out manufacturing-practice violations there.

For a design guide, Emcure shows how a contract manufacturer can build its own name in Indian pharmacies, then carry other companies’ brands as well. Compare Lupin, another Indian generics maker built by its founder, and Cipla. For this guide we use plum, coral and cream with a serif, an unofficial interpretation; no product or logo is reproduced.

Keep Emcure’s identity on hand — save it to a board in the Made Good inspiration library.